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The interleukin 1receptors (IL-IR) on the human B lymphoma RAJI and on the murine thymoma EL4-6.1 have been 
characterized. Equilibrium binding analysis using both 12SI-labeled IL-I~ and IL-lfl showed that RAJI cells have a higher 
number of binding sites/ceil for IL-lfl (2400, Kd 2.2 nM) than for IL-Ict (316,/~ 0.13 nM). On the other hand, EL4-6.1 
cells have more receptors/cell forIL-I~ (22 656, K~ l nM) than for IL-lfl (2988,/~ 0.36 nM). Dexamethasone (DXM) 
induced on RAJI cells a time-dependent increase inbinding sites for both IL-lfl and IL-I~ without affecting their binding 
affinities. However, while receptor-bound ~zsI-IL-l~ was displaced with equal ettlcien~y b both IL-I forms, only unla- 
beled IL-lfl could effectively displace 12H-IL-l//. Cross-linking experiments indicated that RAJI cells have a predominant 
IL-IR of about 68 kDa, while EL4-6.1 cells have an IL-l-binding polypeptide of80 kDa. These results uggest that B 
and T cells possess tructurally different IL-1R with distinct binding properties for IL-I~ and IL-lfl. 
Interleukin l receptor; Interleukin lu; Interleukin lfl; (RAJI B lymphoma, EIA-6.1 thymoma) 
1. INTRODUCTION 
The term interleukin 1 (IL-1) describes a family 
of at least two proteins, termed t~ and B, which 
share a wide array of both immunomodulatory 
and inf lammatory activities [1]. IL-lt~ and IL- IB 
exert their biological activities through the interac- 
tion with specific receptors on the surface of target 
cells. Although they are only poorly homologous 
in their primary sequences, the two IL-1 isoforms 
have been reported to bind a common class of 
receptors on a variety of cell types including T and 
B cells [2] and fibroblasts [3]. The sequence of a 
cDNA encoding an 80 kDa polypeptide responsi- 
ble for the binding of IL-1 on routine EL4-6.1 
thymoma has been recently reported [4]. In the 
same study, COS cells expressing this recombinant 
IL-1R polypeptide have been shown to bind IL-lo< 
and IL- IB with markedly different affinities [4]. It 
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is thus conceivable that IL-1R could be formed of 
a complex comprising more than one polypeptide 
within which IL-h~ and IL-I/~ bind in a different 
fashion. Moreover, it has recently been shown that 
differences in the molecular characteristics of 
IL-1R occur between B and T cells [5]. 
Here, we have analyzed the binding parameters 
and some biochemical characteristics of IL-1R on 
the surface of both untreated and dexamethasone 
(DXM)-treated human RAJ I  B lymphoma nd on 
the murine EL4-6.1 thymoma using iodine-labeled 
IL -hr  and IL-1/3. Our results confirm the observa- 
tion that B and T cells have structurally distinct 
IL-1R and suggest for the first time that the IL-1R 
present on the surface of these cells possess dif- 
ferent binding properties for IL-lo< and IL-1B. 
2. MATERIALS AND METHODS 
2.1. Cells 
RAJI human B cell lymphoma was obtained from Dr G.P. 
Pantaleo (Ludwig Institute, Lausanne, Switzerland) and 
cultured in RPMI 1640 medium (Gibco, Paisley, Scotland) sup- 
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plemented with 10% heat-inactivated foetal bovine serum 
(FBS), 50/,g/ml gentamycin sulphate, 25 mM Hepes buffer 
and 2 mM L-glutamine. EL4-6.1 murine thymoma was ob- 
tained from Dr H.R. MacDonald (Ludwig Inst., Lausanne) and 
cultured as in [6]. For stimulation with giucocorticoids, RAJI 
cells were washed in fresh medium and then suspended at2.5 
× 105 cells/ml. Dexamethasone acetate (DXM) (Sigma, St. 
Louis, MO) was dissolved in DMSO at 2 mg/ml and then 
diluted into the culture medium at the desired concentration. 
Control cultures received the same concentration of DMSO 
alone. 
2.2. Radiolabeling of IL-lo< and IL-I/Y 
Human recombinant IL-lo< (Biogen, Geneva) was 
radioiodinated using the chloramine T method exactly as 
described by Lowenthal and MacDonald [6]. Human recombi- 
nant IL-I/b' (Sclavo-De.Bi., Siena nd Cassina de' Pecchi, Italy), 
expressed inE. coli and purified as in [7], was radioiodinated 
with [~2Sl]di-iodo B lton-Hunter (4400 Ci/mmol, New England 
Nuclear, Boston, MA) following the manufacturer's in truc- 
tions. The specific activities obtained were routinely around 1.2 
x 106 cpm/pmol for IL-l~'and 5.4 x 106 cpm/pmol for IL-lo<. 
The biological activity of labeled IL-1 was monitored using the 
DI0.G4.1 proliferation assay [8] and found to be the same for 
both 125I-IL-la and 12sI-IL-l~) (not shown). 
2.3. Binding assay 
Cells were suspended at 1 x 107/ml in RPMI containing 10070 
FBS and 0.02070 sodium azide (binding medium). Aliquots of 
5 x 105 cells were incubated for 3 h at room temperature (RT) 
under constant gentle agitation. At the end of the incubation 
unbound radioactivity was separated from cell-bound radioac- 
tivity with centrifugation  a microfuge (Beckman, Fullerton, 
CA) through an oil gradient (80070 silicone and 20070 paraffin). 
Non-specific binding was determined by adding a 500-fold 
molar excess of unlabeled IL-la or IL-IB. All the calculations 
and Scatchard analysis were performed according to Munson 
and Rodbard [9l. 
2.4. Covalent cross-linking and gel electrophoresis 
~25I-IL-ltr and 125I-IL-l/~ were cross-linked tointact cells with 
disuccinimidyl suberate (DSS) or dithiobis(disuccinimidyl pro- 
pionate) (DSP) (Pierce, Rockville, MD) as described in [3]. 
Briefly, cells suspensions (10 7 ceils/ml) in binding medium were 
incubated with ~25I-IL-ltr or -B (2.3 nM) for 3 h at room 
temperature with or without a 500-fold molar excess of unla- 
beled IL-I/~. After washing the unbound IL-1, DSS or DSP 
(50 mg/ml in DMSO) were added to a final concentration f
2 mg/ml, and the reaction was allowed to proceed for 45 rain 
at room temperature. Cells were lysed with 50/A of PBS con- 
taining 7.5raM 3-(3-cholamidopropyl)dimethylarnmonio-1- 
propanesulphonate (CHAPS) (Serva, Heidelberg), 1 mM 
PMSF, 10 pg/ml of aprotinin, leupeptin, chymostatin a d anti- 
pain (Boehringer Mannheim, Mannheim, FRG), and centri- 
fuged in an Eppendorf apparatus for 5 rain. The supernatant 
was denatured with Laemmli sample buffer [10], with the ex- 
ception that 2-mercaptoethanol wasomitted for samples cross- 
linked with DSP. SDS-PAGE was run on 8 or 10070 gels using 
coloured molecular mass markers (Amersham, Little Chalfont, 
England). Dried gels were exposed at -40°C using Kodak 
XAR-5 autoradiographic films. 
3. RESULTS 
The specific binding of increasing amounts of 
125I-IL-lo~ or 125I-IL-1/5' added to aliquots of 5 x 
105 RAJ I  cells is shown in fig. 1. Scatchard analysis 
(see insets) of the typical experiment shown in- 
dicated that RAJ I  cells have 316 receptors/cell (Kd 
= 0.13 nM) for IL - I~ and 2400 receptors/cell (Kd 
---- 2.2 nM) for IL-1/Y. The same kind of ex- 
periments were then performed on the murine 
thymoma EL4-6.1. In a representative experiment 
reported in fig.2, the specific binding obtained 
with increasing amounts of 125I-IL-h~ (A) or 125I= 
IL - I~  (B) is plotted. Scatchard analysis (insets) 
showed that EL4-6.1 cells have 22656 recep- 
tors/cell  (Kd = 1 nM) for IL- la, and 2988 recep- 
tors/cel l  (Kd = 0.36 nM) for IL-I~'. 
Glucocorticoid hormones have been recently 
reported to increase the number  of binding sites 
for IL-1 in human peripheral B lymphocytes [11]. 
RAJ I  B lymphoma cells were thus incubated with 
400 nM DXM and, after different ime intervals, 
the specific b inding of a fixed amount  of 125I-IL-1~' 
(70000 cpm) was determined. As shown in fig.3A 
the specific binding remained similar to the control 
level for 6 h after DXM addit ion and constantly 
increased thereafter. In al l  subsequent experiments 
RA J I  ceils were thus stimulated with DXM for 
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Fig.l. Equilibrium binding analysis on RAJI cells. Specific 
binding of increasing amounts of 125I-IL-l~ (A) or 125I-IL-IB 
(B) to aliquots of 5 × 105 cells was determined by subtracting 
non-specific binding obtained in the presence of a 500-fold 
molar excess of unlabeled IL-la or -~'. Insets: Scatchard 
analyses. 
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Fig.2. Equilibrium binding analysis on EL4-6.1 cells. Specific 
binding of increasing amounts of 12Sl-IL-lot (A) or ~2sI-IL-l/~ 
(B) was determined as described in fig.1. 
48 h. The specific binding of increasing amounts 
of 12sI-IL-l- (fig.3B) or 125I-IL-1/3 (fig.3C) was 
then determined on RAJI cells incubated with 
400 nM DXM for 48 h. Scatchard analysis (see in- 
sets) showed that DXM-stimulated RAJI cells have 
1800 receptors/cell (Kd = 0.12 nM) for IL-1, and 
9960 receptors/cell (Kd = 2.1 riM) for IL-1/3. Thus 
incubation with the glucocorticoid hormone in- 
duced an increase in specific binding for both 
isoforms of IL-1 without affecting their affinities 
for the ligand. 
To characterize further the IL-1R on DXM- 
treated RAJI cells, competition binding ex- 
periments were performed. Fig.4 demonstrates the 
displacement of receptor-bound 125I-IL-1a (A) or 
125I-IL-1~ (B) by a wide range of doses of either 
unlabeled IL-lt~ or IL-I~. Both isoforms were 
equally potent in the competition with 125I-IL-la, 
but only unlabeled IL-1/~ could efficiently displace 
the receptor-bound 125I-IL-1/3. 
A partial biochemical characterization of the 
polypeptides involved in binding of IL-I~ and 
IL-1/3 on the surface of both RAJI and EL4-6.1 
cells was then undertaken. The electrophoretic pat- 
tern on 8°/o SDS-PAGE of 125I-IL-ltr or 125I-IL-1~' 
cross-linked to RAJI cells using DSS is shown in 
fig.5A. With both 125I-IL-1~ and 125I-IL-1~, a ma- 
jor high molecular mass complex of about 85 kDa 
was observed which was not present when cells 
were incubated in the presence of a 500-fold molar 
excess of unlabeled IL-1. Treatment with DXM 
resulted in an increase in intensity of the specific 
bands obtained with both t25I-IL-lt~ and 125I- 
IL-1/~, in agreement with the increase in receptor 
number observed in the equilibrium binding ex- 
periments. The electrophoretic pattern on 8% 
SDS-PAGE of the cross-linked products obtained 
with DSP on RAJI cells is reported in fig.5B. With 
125I-IL-1/~ a predominant specific band at about 
85 kDa was obtained, in agreement with the results 
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Fig.3. Characterization f IL-IR on 48 h DXM-stimulated RAJI cells. (A) Specific binding of ]2~I-IL-l~' (70000 cpm) to RAJI cells 
at different time intervals after stimulation with 400 nM DXM. Each bar represents the mean of duplicate determinations. The specific 
binding of increasing amounts of lzsI-IL-la (B) or ~2sI-IL-I~ (C) to RAJI cells stimulated for 48 h with DXM was determined as 
described in fig.l. 
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Fig.4. Competition binding analysis on RAJI cells stimulated 
with DXM for 48 h. Cells were incubated with 30000 cpm ~25I- 
IL-lct (A) or 41000cpm 1251-1L-IB (B) with or without 
increasing concentrations of unlabeled IL-h~ (m) or IL-IB (r~). 
After subtraction of non-specific binding the amount of bound 
radioligand at each dose was compared to that obtained in the 
absence of the unlabeled competitor. Each point is the mean of 
duplicate determinations. 
obtained using DSS, while cross-linking of 125I- 
IL-I~ gave a predominant high molecular mass 
complex of about 145 kDa and a much less intense 
band at 85 kDa. Treatment with DXM resulted in 
an increase in intensity of the bands at 145 and 
85 kDa for 125I-IL-la~, and of the 85 kDa product 
obtained with 125I-IL-1/~. 
In order to compare the structural properties of 
the IL-1R on RAJI B lymphoma nd EL4-6.1 
thymema, the same amounts of 125I-IL-hr or -~ 
were incubated with EL4-6.1 in the presence of 
DSS. The electrophoretic pattern of the cross- 
linked products on 10070 SDS-PAGE is reported in 
fig.5C. A major product at about 98 kDa is pre- 
sent with EL4-6.1 for 125I-IL-lot and 125I-IL-1/3. 
The intensity of the bands obtained with IL-1~ was 
much higher than those obtained with IL-I•, again 
in agreement with the equilibrium binding analysis 
that showed a greater number of binding sites for 
IL-I~ on the surface of EL4-6.1 thymoma. The 
specificities of the bands were assessed in the 
presence of a 500-fold excess of unlabeled IL-1 
(not shown). 
4. DISCUSSION 
In this study, evidence isprovided that the IL-1R 
have distinct binding properties for IL-la and 
IL-1/3 on the surface of both B and T cells. In fact, 
the B lymphoma RAJI has a low number of recep- 
tors for IL-la (=300 sites/cell) and a higher 
number of receptors for IL-1/3 (=2500 sites/cell) 
(fig. 1), while EL4-6.1 thymoma (fig.2) possesses a 
greater number of binding sites for IL-hz (= 20000 
sites/cell) than for IL-1/3 (= 3000 sites/cell). It was 
also observed that RAJI B lymphoma binds IL-h~ 
with much higher affinity (=0.1 nM) than IL-1/~ 
(= 2 nM) while EL4-6.1 thymoma binds IL-I~ with 
lower affinity (= 1 riM) than IL-1B (=0.4 riM). 
The number of specific binding sites for both 
IL-1 isoforms on RAJI cells can be increased by in- 
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Fig.5. Autoradiography of the 8°70 SDS-PAGE of cross-linked products obtained using DSS (A) or DSP (B) on control and 48 h DXM- 
stimulated RAJI cells incubated with ~25I-IL-hz or 125I-IL-l~' in the absence ( - )  or presence ( + ) of a 500-fold molar excess of IL-1B. 
((2) Autoradiography of the 10070 SDS-PAGE of the cross-linked products obtained using DSS on EL4-6.1 incubated with 125I-IL-l~ 
or 125I-IL-l~'. 
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cubation with glucocorticoids, but the binding 
parameters of IL-ltr and IL-1B are still distinct. In 
fact, after 48 h treatment with DXM, the number 
of receptors for IL-la (=2000 sites/cell; Kd = 
0.1 nM) is still lower than that of receptors for 
IL-I~ (= 10000 sites/cell; Kd = 2 nM). 
This apparent dissociation was further con- 
firmed by the results of competition binding ex- 
periments. In fact, while the receptor-bound 
125I-IL-ltr could be displaced by both forms of 
unlabeled IL-1, 125I-IL-IB was effectively dis- 
placed only by unlabeled IL-ll3. 
Taken together the results of binding ex- 
periments showed that human B cells and murine 
T cells have contrasting properties in the binding 
of the two IL-1 isoforms, and suggested that RAJI 
cells have an IL-1R to which IL-lc~ and IL-I~ bind 
at distinct although partially overlapping sites. 
Some preliminary information on the structural 
characteristics of the specific binding sites for IL-1 
on both RAJI and EL4-6.1 cells was provided by 
affinity cross-linking experiments. On RAJI cells, 
the IL-1R, after subtraction of the molecular mass 
of IL-1, appeared to consist of a major component 
of about 68 kDa binding both IL-ll3 and IL-loe. 
Our results are thus in agreement with the recent 
report of a 68 kDa IL-1R on RAJI cells observed 
by using 125I-IL-lfl cross-linked with DSS [5]. An 
IL-l-binding polypeptide of about 130 kDa was 
also observed mainly with 125I-IL-ltr cross-linked 
using DSP. The identity of this high molecular 
mass component is presently unknown, however 
we cannot exclude the possibility that it could be a 
dimer of the IL-1/IL-1R generated uring the 
cross-linking procedure. 
The cross-linking experiments confirmed the 
reported difference in molecular mass of IL-1R 
between human RAJI B lymphoma nd murine T 
ceils [5]. In fact the predominant band observed 
with EL4-6.1 using both IL-loe and -~, after sub- 
traction of the molecular mass of IL-1, accounted 
for the presence of an 80 kDa IL-1R, as described 
previously in this cell line [12]. 
In conclusion, the present data suggest that the 
IL-1R present on both B and T cells possess 
distinct binding parameters for IL-lte and IL-1/3 
and also confirm and extend the notion of struc- 
tural heterogeneity between the IL-IR of different 
cell lineages. 
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